Skip to main content
LEAP THERAPEUTICS, INC. logo

LEAP THERAPEUTICS, INC. — Investor Relations & Filings

Ticker · LPTX ISIN · US52187K2006 LEI · 549300T31SMMJ2DDLI13 US Manufacturing
Open in API
Filings indexed 584 across all filing types
Latest filing 2021-01-07 Director's Dealing
Country US United States of America
Listing US LPTX

About LEAP THERAPEUTICS, INC.

https://www.leaptx.com/

Leap Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing targeted and immuno-oncology therapeutics for cancer. Its most advanced clinical candidate, DKN-01 (sirexatamab), is a humanized monoclonal antibody targeting the Dickkopf-1 (DKK1) protein, being developed for patients with esophagogastric, gynecologic, and colorectal cancers. The company's pipeline also includes FL-301, a monoclonal antibody targeting Claudin18.2 for gastric and pancreatic cancer, and FL-501, a preclinical antibody targeting the growth and differentiation factor 15 (GDF-15) protein.

Recent filings

Filing Released Lang Actions
OWNERSHIP DOCUMENT
Director's Dealing
2021-01-07 English
OWNERSHIP DOCUMENT
Director's Dealing
2020-12-31 English
SCHEDULE 13G
Major Shareholding Notification
2020-12-28 English
FORM 8-K
Earnings Release Classification · 95% confidence The document is a Form 8-K filed with the SEC, dated November 12, 2020, by Leap Therapeutics, Inc. It announces the company's financial results for the quarter ended September 30, 2020, and includes a press release as an exhibit. The text explicitly states that the information is a current report and the press release is furnished as an exhibit. The document does not contain the full financial statements or detailed financial analysis itself but rather announces the results and provides the press release. Given the length of the document (4359 characters) and the nature of the content (announcement of quarterly financial results via press release), this fits the definition of an Earnings Release (ER) rather than a full Interim/Quarterly Report (IR) or Annual Report (10-K).
2020-11-12 English
FORM 10-Q
Interim / Quarterly Report Q3 2020
2020-11-12 English
FORM 8-K
Regulatory Filings Classification · 95% confidence The document is a Form 8-K filed with the SEC, which is a current report used to announce unscheduled material events or corporate changes. The text mentions the filing of two press releases as exhibits related to updated data presentations. There are no financial statements or detailed financial data included, and the document is relatively short (3881 characters). It serves as a regulatory announcement of events rather than a full financial report or earnings release. Therefore, it fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous filings that do not fit other specific categories.
2020-11-09 English

Browse filings by year

12 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.